Semaglutide

5 mg

$84.99 CAD

A GLP-1 receptor agonist whose mechanism is documented in official labelling and whose weight outcomes come from a separate 68-week trial.

Format: 5 mg
Use: Laboratory research

View cart

For laboratory research only · Not for human consumption

What is Semaglutide?

Semaglutide is a GLP-1 receptor agonist. In plain terms, official labelling describes it acting on two fronts that are worth keeping apart: appetite and calorie intake on one side, and blood-glucose regulation on the other. This listing is laboratory research material — it is not Ozempic, not Wegovy and not an authorized medicine.

Key concepts: GLP-1 receptor · Endpoint · Adverse event

How it works and what researchers study

Mechanism statements come from regulated product labelling; outcome statements come from randomized trials that specify population, comparator, endpoint and duration, and that report adverse effects alongside benefits.

What the evidence shows

Official labelling describes two separate things. For appetite, it states that GLP-1 regulates appetite and calorie intake, that GLP-1 receptors are present in brain regions involved in appetite regulation, and that semaglutide decreases calorie intake likely through an effect on appetite. For blood glucose, it separately describes glucose-dependent insulin secretion and reduced glucagon secretion, which lower blood glucose, and describes delayed gastric emptying as a further separate effect. A 2021 trial in 1,961 adults with overweight or obesity without diabetes, over 68 weeks with a lifestyle intervention, reported body-weight reduction and gastrointestinal adverse effects.

Limits of the evidence

United States labelling is not evidence of Canadian authorization; that is a separate database check.
Trial findings belong to the enrolled population and the 68-week study period.
Both documents describe approved pharmaceutical products, not research material supplied for laboratory use.

References

Official United States prescribing information for semaglutide injection (Ozempic). United States labelling only; it is not Canadian authorization evidence. View source
Official United States prescribing information for semaglutide injection 2.4 mg (Wegovy), sections 12.1 and 12.2. United States labelling only; it is not Canadian authorization evidence. View source
Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021. doi:10.1056/NEJMoa2032183 View source
Health Canada. Drug Product Database: the official list of drug products authorized for sale in Canada. View source

Compound science vs product quality

The research described here studied the compound under laboratory or clinical conditions. No cited paper or label tested a Proof Line Peptides vial. Product-level questions — identity, stated quantity and lot-matched documentation — are answered by records supplied with the material, not by published studies.

Questions about Semaglutide

Is this the same as an approved semaglutide medicine?: No. This is research material for laboratory use. Approved medicines are specific manufactured products with their own authorizations and labelling.
How is reduced calorie intake explained?: Labelling attributes it to an effect on appetite, with GLP-1 receptors present in brain regions that regulate appetite. That is a different pathway from the glucose-lowering actions — glucose-dependent insulin secretion and reduced glucagon — and from delayed gastric emptying, which the label describes separately.
What adverse effects were reported in the trial?: Gastrointestinal adverse effects were reported alongside the body-weight reduction.